Omeros Ireland Limited
- Address
- Ormond Building, 31-36 Ormond Quay Upper
Sponsor Overview
Specializations
Paroxysmal nocturnal hemoglobinuria
Clinical research activity is centered on paroxysmal nocturnal hemoglobinuria, with attention to the management of complement-mediated hemolysis and related disease burden in patients with an incomplete response to existing C5 inhibitor therapy.
- Paroxysmal nocturnal hemoglobinuria
- Complement system inhibition
- Hemolytic anemia
The sponsor’s trial portfolio reflects a focused interest in therapies for rare hematologic disorders, particularly treatment pathways aimed at improving control of intravascular hemolysis and associated clinical symptoms.
Hematology and rare blood disorders
The sponsor maintains a therapeutic emphasis in hematology, with research directed toward rare blood diseases that require targeted intervention and careful assessment of disease-specific response.
- Rare hematologic diseases
- Blood cell destruction
- Transfusion-related disease burden
Its clinical interest includes conditions where persistent anemia, fatigue, and other consequences of chronic hemolysis remain important therapeutic concerns.
Complement-targeted therapy
Research activity is aligned with complement pathway modulation, particularly approaches designed to address disease mechanisms that remain active despite prior treatment with established terminal complement inhibitors.
- Complement pathway modulation
- Terminal complement inhibition
- Residual disease activity
The sponsor’s therapeutic focus includes agents intended to refine control of immune-mediated hemolysis in a highly specific hematologic setting.
Specialty clinical development
As a pharmaceutical company based in Dublin, Ireland, the sponsor is active in a narrowly defined clinical development area involving specialty medicine for rare disease populations.
- Rare disease therapeutics
- Specialty hematology
- Patient-focused blood disorder research
Its research landscape is concentrated on therapies intended for patients with limited treatment options in complement-driven hematologic disease.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Evaluation of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients with Sub-optimal Response to C5 Inhibitor Ravulizumab: A Phase 2 Study |  Germany Greece | Not Recruiting |
Data & Insights
This sponsor works with 0 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 5 sites across their trial portfolio.
Therapeutic Focus
- 1.Immune System Diseases1 trial322 other sponsors
Partnered Research Centres
5 centres- Address
- Exochi, 570 10 Thessaloniki
- Address
- Albert-Einstein-Allee 23, Eselsberg, 89081 Ulm
- Address
- Fetscherstrasse 74, Johannstadt-Nord, 01307 Dresden
- Address
- Pauwelsstrasse 30, 52074 Aachen
- Address
- University Hospital of Patras, BMT Unit, 5th Floor, 26500 Pátrai
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Omeros Ireland Limited.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.